loxapine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
psychoactive	1613	1977-10-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: loxapine loxapin oxilapine loxapine succinate cloxazepine loxitane adasuve loxapine hydrochloride loxapine HCl loxipine maleate	An antipsychotic agent used in SCHIZOPHRENIA. Molecular weight: 327.81 Formula: C18H18ClN3O CLOGP: 3.68 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 28.07 ALOGS: -3.50 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

loxapine
loxapin
oxilapine
loxapine succinate
cloxazepine
loxitane
adasuve
loxapine hydrochloride
loxapine HCl
loxipine maleate

An antipsychotic agent used in SCHIZOPHRENIA.

Molecular weight: 327.81
Formula: C18H18ClN3O
CLOGP: 3.68
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 28.07
ALOGS: -3.50
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
9.10	mg	Inhal.powder
0.10	g	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	0.02 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
Feb. 25, 1975	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Poisoning deliberate	434.26	37.30	110	4396	11108	63473408
Coma	398.38	37.30	155	4351	64209	63420307
Neuroleptic malignant syndrome	244.12	37.30	71	4435	11985	63472531
Extrapyramidal disorder	182.23	37.30	58	4448	13226	63471290
Hepatocellular injury	144.68	37.30	59	4447	27322	63457194
Cholestasis	130.58	37.30	56	4450	29378	63455138
Oculogyric crisis	124.38	37.30	28	4478	1693	63482823
Intestinal obstruction	118.29	37.30	53	4453	30846	63453670
Somnolence	117.96	37.30	99	4407	178586	63305930
Altered state of consciousness	102.08	37.30	45	4461	25185	63459331
Toxicity to various agents	88.84	37.30	98	4408	247152	63237364
Hypothermia	84.68	37.30	33	4473	13548	63470968
Intentional overdose	84.36	37.30	57	4449	74095	63410421
Asphyxia	80.65	37.30	26	4480	6155	63478361
Catatonia	80.17	37.30	24	4482	4453	63480063
Miosis	76.21	37.30	26	4480	7327	63477189
Tachycardia	70.74	37.30	62	4444	118094	63366422
Benzodiazepine drug level increased	69.40	37.30	12	4494	180	63484336
Pneumonia aspiration	68.75	37.30	38	4468	34502	63450014
Cardio-respiratory arrest	67.95	37.30	46	4460	59913	63424603
Galactorrhoea	60.48	37.30	19	4487	4136	63480380
Hepatic cytolysis	57.55	37.30	26	4480	15381	63469135
Hyperprolactinaemia	57.46	37.30	18	4488	3882	63480634
Faecaloma	55.59	37.30	21	4485	7920	63476596
Brain death	55.56	37.30	17	4489	3393	63481123
Rhabdomyolysis	55.29	37.30	36	4470	43915	63440601
Hyperthermia	49.23	37.30	20	4486	9136	63475380
Antipsychotic drug level above therapeutic	49.15	37.30	12	4494	1031	63483485
Suicide attempt	49.04	37.30	38	4468	60880	63423636
Drug reaction with eosinophilia and systemic symptoms	48.24	37.30	30	4476	33806	63450710
Overdose	47.15	37.30	49	4457	115029	63369487
Sedation	46.89	37.30	31	4475	38778	63445738
Intestinal pseudo-obstruction	45.57	37.30	11	4495	901	63483615
Drug interaction	44.41	37.30	67	4439	229064	63255452
Dystonia	44.37	37.30	21	4485	13798	63470718
Hypotension	43.61	37.30	73	4433	272531	63211985
Urinary retention	43.53	37.30	27	4479	30274	63454242
Cardiogenic shock	42.02	37.30	22	4484	17910	63466606
Poisoning	41.49	37.30	20	4486	13680	63470836
Wrong patient received product	40.24	37.30	12	4494	2195	63482321
Myocarditis septic	39.65	37.30	6	4500	36	63484480
Amenorrhoea	37.87	37.30	17	4489	9897	63474619

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	387.57	38.28	189	7096	45489	34904157
Antipsychotic drug level below therapeutic	373.07	38.28	90	7195	2457	34947189
Therapeutic product effect variable	360.83	38.28	87	7198	2369	34947277
Disinhibition	356.86	38.28	91	7194	3135	34946511
Akathisia	331.00	38.28	105	7180	8004	34941642
Obsessive-compulsive disorder	329.75	38.28	96	7189	5468	34944178
Euphoric mood	302.14	38.28	90	7195	5551	34944095
Increased appetite	277.73	38.28	90	7195	7339	34942307
Poisoning deliberate	191.19	38.28	69	7216	7775	34941871
Suicide attempt	185.12	38.28	110	7175	39006	34910640
Neuroleptic malignant syndrome	172.31	38.28	81	7204	17853	34931793
Leukaemia	137.02	38.28	47	7238	4556	34945090
Therapeutic product effect incomplete	133.90	38.28	99	7186	50442	34899204
Extrapyramidal disorder	126.22	38.28	59	7226	12821	34936825
Hepatocellular injury	125.06	38.28	70	7215	22141	34927505
Wrong patient received product	123.38	38.28	38	7247	2616	34947030
Dyslipidaemia	114.74	38.28	47	7238	7441	34942205
Leukopenia	112.81	38.28	98	7187	62758	34886888
Rhabdomyolysis	111.84	38.28	101	7184	68062	34881584
Obesity	102.02	38.28	51	7234	12827	34936819
Prescribed overdose	98.86	38.28	47	7238	10600	34939046
Hypothermia	98.43	38.28	47	7238	10701	34938945
Miosis	94.40	38.28	44	7241	9491	34940155
Weight increased	92.27	38.28	105	7180	92928	34856718
Intestinal obstruction	92.01	38.28	58	7227	22764	34926882
Product use in unapproved indication	84.84	38.28	113	7172	117386	34832260
Toxicity to various agents	83.10	38.28	149	7136	200213	34749433
Somnolence	81.96	38.28	108	7177	111008	34838638
Faecaloma	76.45	38.28	32	7253	5345	34944301
Hyperleukocytosis	61.74	38.28	21	7264	1981	34947665
Fatigue	58.92	38.28	5	7280	370648	34578998
Colitis ischaemic	58.31	38.28	28	7257	6447	34943199
Pneumonia aspiration	53.26	38.28	54	7231	41849	34907797
Subileus	52.12	38.28	21	7264	3182	34946464
Schizoaffective disorder	49.22	38.28	16	7269	1311	34948335
Choking	49.18	38.28	23	7262	4992	34944654
Psychotic symptom	48.76	38.28	17	7268	1726	34947920
Congestive cardiomyopathy	48.67	38.28	26	7259	7484	34942162
Necrotising colitis	48.12	38.28	15	7270	1073	34948573
Electrocardiogram QT prolonged	45.29	38.28	49	7236	40903	34908743
Hyperthermia	42.89	38.28	27	7258	10550	34939096
Tachycardia	42.86	38.28	69	7216	84703	34864943
Bradypnoea	40.76	38.28	17	7268	2812	34946834
Blood creatine phosphokinase increased	39.98	38.28	48	7237	44809	34904837
Bladder dilatation	39.63	38.28	14	7271	1478	34948168
Diarrhoea	39.55	38.28	16	7269	389896	34559750
Cardio-respiratory arrest	39.53	38.28	53	7232	55220	34894426

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	794.55	33.35	344	10162	100305	79633577
Poisoning deliberate	599.50	33.35	181	10325	18647	79715235
Neuroleptic malignant syndrome	397.95	33.35	146	10360	27413	79706469
Extrapyramidal disorder	315.72	33.35	117	10389	22562	79711320
Hepatocellular injury	265.06	33.35	128	10378	47465	79686417
Somnolence	213.89	33.35	206	10300	238775	79495107
Rhabdomyolysis	191.59	33.35	136	10370	102995	79630887
Intestinal obstruction	187.39	33.35	98	10408	42922	79690960
Hypothermia	186.04	33.35	80	10426	22666	79711216
Miosis	178.43	33.35	70	10436	15719	79718163
Wrong patient received product	166.77	33.35	49	10457	4569	79729313
Faecaloma	136.76	33.35	53	10453	11511	79722371
Akathisia	136.61	33.35	55	10451	13204	79720678
Pneumonia aspiration	132.84	33.35	92	10414	66875	79667007
Altered state of consciousness	120.76	33.35	74	10432	43748	79690134
Catatonia	110.22	33.35	42	10464	8714	79725168
Tachycardia	106.57	33.35	124	10382	177644	79556238
Antipsychotic drug level below therapeutic	101.00	33.35	25	10481	1213	79732669
Asphyxia	98.36	33.35	42	10464	11678	79722204
Cardio-respiratory arrest	97.63	33.35	94	10412	108416	79625466
Hyperthermia	95.75	33.35	47	10459	17990	79715892
Cholestasis	92.68	33.35	67	10439	52042	79681840
Suicide attempt	90.43	33.35	80	10426	82852	79651030
Toxicity to various agents	90.33	33.35	182	10324	421358	79312524
Therapeutic product effect variable	89.00	33.35	25	10481	1984	79731898
Fatigue	88.04	33.35	10	10496	929717	78804165
Oculogyric crisis	87.91	33.35	27	10479	2925	79730957
Choking	87.35	33.35	39	10467	12062	79721820
Disinhibition	86.96	33.35	26	10480	2572	79731310
Subileus	85.37	33.35	31	10475	5623	79728259
Hyperleukocytosis	82.53	33.35	25	10481	2585	79731297
Necrotising colitis	79.82	33.35	20	10486	1020	79732862
Congestive cardiomyopathy	75.66	33.35	35	10471	11745	79722137
Bladder dilatation	74.38	33.35	22	10484	2097	79731785
Hepatic cytolysis	72.61	33.35	45	10461	27106	79706776
Drug abuse	66.65	33.35	94	10412	162597	79571285
Blood creatine phosphokinase increased	66.59	33.35	61	10445	66029	79667853
Euphoric mood	62.56	33.35	27	10479	7699	79726183
Electrocardiogram QT prolonged	62.53	33.35	68	10438	90318	79643564
Obsessive-compulsive disorder	62.47	33.35	25	10481	5902	79727980
Benzodiazepine drug level increased	59.51	33.35	12	10494	224	79733658
Intentional overdose	58.60	33.35	71	10435	105889	79627993
Pain	58.59	33.35	11	10495	703791	79030091
Bradypnoea	58.53	33.35	24	10482	6028	79727854
Drug interaction	58.50	33.35	152	10354	415031	79318851
Urinary retention	58.47	33.35	53	10453	56577	79677305
Sedation	56.41	33.35	50	10456	51845	79682037
Poisoning	55.48	33.35	37	10469	25235	79708647
Agitation	52.20	33.35	65	10441	99650	79634232
Dyslipidaemia	52.02	33.35	27	10479	11606	79722276
Galactorrhoea	51.37	33.35	19	10487	3627	79730255
Product use in unapproved indication	50.99	33.35	106	10400	250253	79483629
Drug reaction with eosinophilia and systemic symptoms	50.96	33.35	52	10454	64192	79669690
Respiratory acidosis	50.10	33.35	26	10480	11174	79722708
Distal intestinal obstruction syndrome	49.92	33.35	13	10493	774	79733108
Faecal vomiting	49.84	33.35	14	10492	1110	79732772
Colitis ischaemic	47.62	33.35	28	10478	15331	79718551
Arthralgia	47.42	33.35	9	10497	571794	79162088
Wrong product administered	46.38	33.35	23	10483	8989	79724893
Intestinal ischaemia	45.96	33.35	26	10480	13244	79720638
Housebound	45.91	33.35	11	10495	465	79733417
Increased appetite	45.67	33.35	25	10481	11953	79721929
Psychotic symptom	45.28	33.35	16	10490	2681	79731201
Dystonia	43.80	33.35	30	10476	21369	79712513
Brain death	43.23	33.35	19	10487	5658	79728224
Aggression	41.78	33.35	42	10464	50916	79682966
Salivary hypersecretion	41.67	33.35	25	10481	14199	79719683
Antipsychotic drug level above therapeutic	41.35	33.35	14	10492	2066	79731816
Psychotic disorder	41.27	33.35	38	10468	41364	79692518
Confusional state	41.26	33.35	113	10393	317884	79415998
Diarrhoea	40.60	33.35	34	10472	880455	78853427
Nausea	40.53	33.35	40	10466	957156	78776726
Hyperprolactinaemia	40.03	33.35	17	10489	4659	79729223
Dyspnoea	39.62	33.35	33	10473	856992	78876890
Dyskinesia	38.74	33.35	38	10468	44735	79689147
Parkinsonism	38.14	33.35	25	10481	16559	79717323
Headache	37.14	33.35	20	10486	653752	79080130
Schizoaffective disorder	37.02	33.35	13	10493	2139	79731743
Rash	37.00	33.35	15	10491	578343	79155539
Myocarditis septic	35.94	33.35	6	10500	36	79733846
Diabetic hyperosmolar coma	35.67	33.35	10	10496	787	79733095
Camptocormia	35.54	33.35	9	10497	479	79733403
Psychomotor skills impaired	35.00	33.35	16	10490	5221	79728661
Drug resistance	34.99	33.35	35	10471	42178	79691704
Hypometabolism	34.69	33.35	7	10499	131	79733751
Obesity	34.54	33.35	32	10474	35093	79698789
Compensatory sweating	34.43	33.35	6	10500	48	79733834

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AH01	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Diazepines, oxazepines, thiazepines and oxepines
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:35476	neuroleptics
CHEBI has role	CHEBI:48561	dopaminergic antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bipolar disorder	indication	13746004	DOID:3312
Schizophrenia	indication	58214004	DOID:5419
Alcoholism	contraindication	7200002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Glaucoma	contraindication	23986001	DOID:1686
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Tardive dyskinesia	contraindication	102449007
Seizure disorder	contraindication	128613002
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Coma	contraindication	371632003
Carcinoma of female breast	contraindication	447782002
Pigmentary Retinopathy	contraindication
Drug Induced CNS Depression	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.59	Basic
pKa2	3.24	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	8.62	CHEMBL	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	7.68	CHEMBL	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.27	PDSP
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.82	PDSP
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.24	PDSP
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.61	PDSP
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	ANTAGONIST	Ki	8	IUPHAR
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.82	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.51	PDSP
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.97	PDSP
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	IC50	7.66	CHEMBL
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	7.13	PDSP
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	8.20	IUPHAR
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	6.68	PDSP
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	5.30	PDSP
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		IC50	5.26	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.38	PDSP
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.91	PDSP
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.09	PDSP
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.83	PDSP
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	6.41	PDSP
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	ANTAGONIST	Ki	8.31	CHEMBL
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		Ki	6.72	PDSP
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	7.28	PDSP
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	6.11	PDSP
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		Ki	5.85	PDSP
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN		IC50	4.70	CHEMBL
Potassium channel subfamily T member 1	Ion channel	Q5JUK3	KCNT1_HUMAN	ACTIVATOR	EC50	5.36	IUPHAR
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.10	PDSP
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	5.46	PDSP
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	7.68	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		IC50	8.22	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		Ki	7.37	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT		IC50	6	CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	6	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	7.80	IUPHAR
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		IC50	7.74	CHEMBL

External reference:

ID	Source
4019805	VUID
N0000147894	NUI
D00794	KEGG_DRUG
27833-64-3	SECONDARY_CAS_RN
4017917	VANDF
4017918	VANDF
4019805	VANDF
C0024056	UMLSCUI
CHEBI:50841	CHEBI
CHEMBL831	ChEMBL_ID
CHEMBL1201155	ChEMBL_ID
DB00408	DRUGBANK_ID
D008152	MESH_DESCRIPTOR_UI
3964	PUBCHEM_CID
205	IUPHAR_LIGAND_ID
2610	INN_ID
54810-23-0	SECONDARY_CAS_RN
LER583670J	UNII
1364415	RXNORM
1308	MMSL
1346	MMSL
196711	MMSL
29026	MMSL
4999	MMSL
5000	MMSL
d00897	MMSL
001522	NDDF
001523	NDDF
001524	NDDF
1971003	SNOMEDCT_US
30745005	SNOMEDCT_US
372789006	SNOMEDCT_US
59270007	SNOMEDCT_US
CHEMBL1201060	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1394	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1394	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1395	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1395	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1396	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1396	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1397	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1397	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0369	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0370	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0371	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0372	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-585	TABLET	5 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-586	TABLET	10 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-587	TABLET	25 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-588	TABLET	50 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	17856-1397	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-436	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-437	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-438	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-439	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4701	CAPSULE	10 mg	ORAL	ANDA	21 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4701	CAPSULE	10 mg	ORAL	ANDA	21 sections
Adasuve	HUMAN PRESCRIPTION DRUG LABEL	1	51097-001	AEROSOL, POWDER	10 mg	RESPIRATORY (INHALATION)	NDA	31 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	62135-492	CAPSULE	5 mg	ORAL	ANDA	13 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	62135-493	CAPSULE	10 mg	ORAL	ANDA	13 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-890	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-890	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-891	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-891	CAPSULE	10 mg	ORAL	ANDA	20 sections